COMPARISON OF THE EFFECT OF RANIBIZUMAB AND TRIAMCINOLONE ACETONIDE IN DIABETIC MACULAR EDEMA WITH EPIRETINAL MEMBRANE IN PSEUDOPHAKIC PATIENTS

Abstract

Background: Macular edema is considered the main cause of visual loss in diabetic retinopathy patients. Aim: The aim of this study is to compare the effectiveness of intravitreal Ranibizumab and Triamcinolone acetonide in management of diabetic macular edema with epiretinal membrane in pseudophakic patients. Methods: In this prospective observational study we compared the efficacy of intravitreal Ranibizumab and Triamcinolone acetonide on 35 eyes of 28 pseudophakic patients with DME with ERM. BCVA, IOP and CMT were recorded to patients before injection and then at 1st, 4th, 8th and 12th week after injection. Results: BCVA improved from 0.5 (0.3–1.4) to reach 0.2 (0–0.9) LogMAR at 12th week postinjection in the Ranibizumab group and improved from 0.6 (0.5–1.6) to 0.4 (0.1–1.5) LogMAR at 12th week postinjection in TA group. IOP changed from baseline of 19.06±2.9 to 23.17±2.68 at 1st week reaching 19.56±1.72 at 12th week (p <0.001) in Ranibizumab group, and changed from baseline of 20.0±2.03 to 23.76±2.31 at 1st week reaching 20.0±1.73 at 12th week in TA group. CMT changed from 414.11±130.44 preinjection to 251.44±67.22 at 12th week postinjection in the Ranibizumab group, and changed from 499.0±175.57 preinjection to 340.24±135.79 at 12th week postinjection in TA group. Conclusion: Our data on the overall treatment response assessed as a change in BCVA, IOP and CMT are in accordance with previous studies, which have proven the clinical efficacy of Ranibizumab and Triamcinolone acetonide for DME therapy.